Cancer Genomics & Proteomics · 2019 · 31 citations · 14 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyNeoplasiaLocal RecurrenceMolecular Classification Of TumorsMolecular Tumor ProfilingOncogene MutationsOncogenic Signaling PathwaysRas Family OncogenesMolecular CharacterizationMolecular Recurrence MarkersMolecular RelapseRecurrenceRecurrence Rate AnalysisTargetable Oncogenic PathwaysTargeted Next-generation Sequencing
BACKGROUND/AIM: Undifferentiated pleomorphic sarcomas (UPSs) are difficult to treat, with a high recurrence rate. However, the genetic and molecular characterization of recurrent UPS has not been identified. PATIENTS AND METHODS: In this study, we investigated the pathogenic and targetable genetic alterations in 16 paired locally pre-recurrent and post-recurrent UPS cases by targeted next-generation sequencing (466 genes). RESULTS: Sequence variations were most frequently found in TP53 (66%), ATRX (34%), and RB1 (28%). In addition, for the first time, recurrent IL7R gene amplification (19%) and KMT2C gene mutation (16%) were detected in UPS. Interestingly, genetic alterations varied with tumor relapse. Importantly, targetable driver variants were found in recurrent UPS. Mutated genes were correlated with the cell cycle, PI3K/mTOR and RAS/MAPK signaling pathways. TMB was also found to be increased after tumor recurrence (4.6 vs. 7.5 mutations/MB, p=0.0343). CONCLUSION: Routine use of targeted next-generation sequencing for recurrent UPS can facilitate timely therapeutic decision-making.
14
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text
Medicine, Cancer Biology, Oncology +17
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal et al. · Science · 2016 · 3.1K citations · Full text
Life Sciences, Immunology, Oncology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17